A composite polymer nanoparticle overcomes multidrug resistance and ameliorates doxorubicin-associated cardiomyopathy

Oncotarget

Volumn 3, Issue 6, 2012, Pages 640-650

  Pramanik, Dipankar ^a   Campbell, Nathaniel R ^a   Das, Samarjit ^a   Gupta, Sonal ^a   Chenna, Venugopal ^a   Bisht, Savita ^b   Sysa Shah, Polina ^a   Bedja, Djahida ^a   Karikari, Collins ^a   Steenbergen, Charles ^a   Gabrielson, Kathleen L ^a   Maitra, Amarnath ^c   Maitra, Anirban ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF BONN   (Germany)

^c INDIAN NATIONAL SCIENCE ACADEMY   (India)

Author keywords

Curcumin; Doxorubicin; Multidrug resistance

Indexed keywords

ANTINEOPLASTIC AGENT; CURCUMIN DOXORUBICIN CONJUGATE; DOXORUBICIN; GLUTATHIONE; GLUTATHIONE PEROXIDASE; NANOCOMPOSITE; NANOCONJUGATE; POLYMER; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASCITES; CANCER CHEMOTHERAPY; CARDIOMYOPATHY; CELL PROLIFERATION; CELL SURVIVAL; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG SAFETY; DRUG SOLUBILITY; ENZYME ACTIVITY; GROWTH INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; MULTIDRUG RESISTANCE; MULTIPLE MYELOMA; NONHUMAN; OUTCOME ASSESSMENT; OVARY CANCER; OXIDATIVE STRESS; PHENOTYPE; PROSTATE CANCER; PROTEIN FUNCTION; TUMOR VOLUME;

EID: 84868617917     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.543     Document Type: Article

References (47)

1. Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PN and Sawyers CL. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science. 2001; 293(5531):876-880.
2. Szakacs G, Paterson JK, Ludwig JA, Booth-Genthe C and Gottesman MM. Targeting multidrug resistance in cancer. Nat Rev Drug Discov. 2006; 5(3):219-234.
3. Durand RE and Olive PL. Resistance of tumor cells to chemo- and radiotherapy modulated by the threedimensional architecture of solid tumors and spheroids. Methods Cell Biol. 2001; 64:211-233.
4. Gottesman MM, Fojo T and Bates SE. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer. 2002; 2(1):48-58.
5. Higgins CF. ABC transporters: from microorganisms to man. Annu Rev Cell Biol. 1992; 8:67-113.
6. Dean M, Rzhetsky A and Allikmets R. The human ATPbinding cassette (ABC) transporter superfamily. Genome Res. 2001; 11(7):1156-1166.
7. Ambudkar SV, Dey S, Hrycyna CA, Ramachandra M, Pastan I and Gottesman MM. Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu Rev Pharmacol Toxicol. 1999; 39:361-398.
8. Cole SP, Bhardwaj G, Gerlach JH, Mackie JE, Grant CE, Almquist KC, Stewart AJ, Kurz EU, Duncan AM and Deeley RG. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science. 1992; 258(5088):1650-1654.
9. Borst P, Evers R, Kool M and Wijnholds J. A family of drug transporters: the multidrug resistance-associated proteins. J Natl Cancer Inst. 2000; 92(16):1295-1302.
10. Paulusma CC, Bosma PJ, Zaman GJ, Bakker CT, Otter M, Scheffer GL, Scheper RJ, Borst P and Oude Elferink RP. Congenital jaundice in rats with a mutation in a multidrug resistance-associated protein gene. Science. 1996; 271(5252):1126-1128.
11. Litman T, Druley TE, Stein WD and Bates SE. From MDR to MXR: new understanding of multidrug resistance systems, their properties and clinical significance. Cellular and molecular life sciences: CMLS. 2001; 58(7):931-959.
12. Honjo Y, Hrycyna CA, Yan QW, Medina-Perez WY, Robey RW, van de Laar A, Litman T, Dean M and Bates SE. Acquired mutations in the MXR/BCRP/ABCP gene alter substrate specificity in MXR/BCRP/ABCP-overexpressing cells. Cancer Res. 2001; 61(18):6635-6639.
13. Doyle LA, Yang W, Abruzzo LV, Krogmann T, Gao Y, Rishi AK and Ross DD. A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sci U S A. 1998; 95(26):15665-15670.
14. Swain SM, Whaley FS and Ewer MS. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer. 2003; 97(11):2869-2879.
15. Lipshultz SE, Lipsitz SR, Sallan SE, Dalton VM, Mone SM, Gelber RD and Colan SD. Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia. J Clin Oncol. 2005; 23(12):2629-2636.
16. Lipshultz SE, Lipsitz SR, Mone SM, Goorin AM, Sallan SE, Sanders SP, Orav EJ, Gelber RD and Colan SD. Female sex and drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer. The New England journal of medicine. 1995; 332(26):1738-1743.
17. Lipshultz SE, Colan SD, Gelber RD, Perez-Atayde AR, Sallan SE and Sanders SP. Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. The New England journal of medicine. 1991; 324(12):808-815.
18. Friedenberg WR, Rue M, Blood EA, Dalton WS, Shustik C, Larson RA, Sonneveld P and Greipp PR. Phase III study of PSC-833 (valspodar) in combination with vincristine, doxorubicin, and dexamethasone (valspodar/VAD) versus VAD alone in patients with recurring or refractory multiple myeloma (E1A95): a trial of the Eastern Cooperative Oncology Group. Cancer. 2006; 106(4):830-838.
19. Tan B, Piwnica-Worms D and Ratner L. Multidrug resistance transporters and modulation. Curr Opin Oncol. 2000; 12(5):450-458.
20. Tsuruo T, Iida H, Tsukagoshi S and Sakurai Y. Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Res. 1981; 41(5):1967-1972.
21. Wu CP, Calcagno AM and Ambudkar SV. Reversal of ABC drug transporter-mediated multidrug resistance in cancer cells: evaluation of current strategies. Curr Mol Pharmacol. 2008; 1(2):93-105.
22. Lee CH. Reversing agents for ATP-binding cassette (ABC) transporters: application in modulating multidrug resistance (MDR). Current medicinal chemistry Anti-cancer agents. 2004; 4(1):43-52.
23. Choi BH, Kim CG, Lim Y, Shin SY and Lee YH. Curcumin down-regulates the multidrug-resistance mdr1b gene by inhibiting the PI3K/Akt/NF kappa B pathway. Cancer Lett. 2008; 259(1):111-118.
24. Chearwae W, Wu CP, Chu HY, Lee TR, Ambudkar SV and Limtrakul P. Curcuminoids purified from turmeric powder modulate the function of human multidrug resistance protein 1 (ABCC1). Cancer Chemother Pharmacol. 2006; 57(3):376-388.
25. Chearwae W, Shukla S, Limtrakul P and Ambudkar SV. Modulation of the function of the multidrug resistancelinked ATP-binding cassette transporter ABCG2 by the cancer chemopreventive agent curcumin. Mol Cancer Ther. 2006; 5(8):1995-2006.
26. Chearwae W, Anuchapreeda S, Nandigama K, Ambudkar SV and Limtrakul P. Biochemical mechanism of modulation of human P-glycoprotein (ABCB1) by curcumin I, II, and III purified from Turmeric powder. Biochem Pharmacol. 2004; 68(10):2043-2052.
27. Anuchapreeda S, Leechanachai P, Smith MM, Ambudkar SV and Limtrakul PN. Modulation of P-glycoprotein expression and function by curcumin in multidrug-resistant human KB cells. Biochem Pharmacol. 2002; 64(4):573-582.
28. Limtrakul P. Curcumin as chemosensitizer. Adv Exp Med Biol. 2007; 595:269-300.
29. Shukla S, Wu CP and Ambudkar SV. Development of inhibitors of ATP-binding cassette drug transporters: present status and challenges. Expert Opin Drug Metab Toxicol. 2008; 4(2):205-223.
30. Misra R and Sahoo SK. Coformulation of doxorubicin and curcumin in poly(D, L-lactide-co-glycolide) nanoparticles suppresses the development of multidrug resistance in K562 cells. Mol Pharm. 2011; 8(3):852-866.
31. Venkatesan N. Curcumin attenuation of acute adriamycin myocardial toxicity in rats. Br J Pharmacol. 1998; 124(3):425-427.
32. Sharma RA, McLelland HR, Hill KA, Ireson CR, Euden SA, Manson MM, Pirmohamed M, Marnett LJ, Gescher AJ and Steward WP. Pharmacodynamic and pharmacokinetic study of oral Curcuma extract in patients with colorectal cancer. Clinical cancer research: an official journal of the American Association for Cancer Research. 2001; 7(7):1894-1900.
33. Bisht S, Mizuma M, Feldmann G, Ottenhof NA, Hong S-M, Pramanik D, Chenna V, Karikari C, Sharma R, Goggins MG, Rudek MA, Ravi R, Maitra A and Maitra A. Systemic Administration of Polymeric Nanoparticle-Encapsulated Curcumin (NanoCurc) Blocks Tumor Growth and Metastases in Preclinical Models of Pancreatic Cancer. Mol Cancer Ther. 2010; 9(8):2255-2264.
34. Bisht S, Khan MA, Bekhit M, Bai H, Cornish T, Mizuma M, Rudek MA, Zhao M, Maitra A, Ray B, Lahiri D, Maitra A and Anders RA. A polymeric nanoparticle formulation of curcumin (NanoCurc™) ameliorates CCl4 induced hepatic injury and fibrosis through reduction of pro-inflammatory cytokines and stellate cell activation. Lab Invest. 2011; 91(9):1383-1395.
35. Ray B, Bisht S, Maitra A, Maitra A and Lahiri DK. Neuroprotective and Neurorescue Effects of a Novel Polymeric Nanoparticle Formulation of Curcumin (NanoCurc™) in the Neuronal Cell Culture and Animal Model: Implications for Alzheimer's disease. J Alzheimers Dis. 2010; 23(1):61-77.
36. David-Beabes GL, Overman MJ, Petrofski JA, Campbell PA, de Marzo AM and Nelson WG. Doxorubicin-resistant variants of human prostate cancer cell lines DU 145, PC-3, PPC-1, and TSU-PR1: characterization of biochemical determinants of antineoplastic drug sensitivity. Int J Oncol. 2000; 17(6):1077-1086.
37. Dalton WS, Durie BGM, Alberts DS, Gerlach JH and Cress AE. Characterization of a New Drug-resistant Human Myeloma Cell Line That Expresses P-Glycoprotein. Cancer Res. 1986; 46(10):5125-5130.
38. Lamy T, Drenou B, Grulois I, Fardel O, Jacquelinet C, Goasguen J, Dauriac C, Amiot L, Bernard M, Fauchet R and et al. Multi-drug resistance (MDR) activity in acute leukemia determined by rhodamine 123 efflux assay. Leukemia: official journal of the Leukemia Society of America, Leukemia Research Fund, UK. 1995; 9(9):1549-1555.
39. Johnson RK, Chitnis MP, Embrey WM and Gregory EB. In vivo characteristics of resistance and cross-resistance of an adriamycin-resistant subline of P388 leukemia. Cancer Treat Rep. 1978; 62(10):1535-1547.
40. Chatterjee K, Zhang JQ, Honbo N and Karliner JS. Doxorubicin Cardiomyopathy. Cardiology. 2010; 115(2):155-162.
41. Srivastava G and Mehta JL. Currying the heart: curcumin and cardioprotection. J Cardiovasc Pharmacol Ther. 2009; 14(1):22-27.
42. Goel A and Aggarwal BB. Curcumin, the Golden Spice From Indian Saffron, Is a Chemosensitizer and Radiosensitizer for Tumors and Chemoprotector and Radioprotector for Normal Organs. Nutr Cancer. 2010; 62(7):919 - 930.
43. Featherstone JM, Speers AG, Lwaleed BA, Hayes MC, Cooper AJ and Birch BR. The nuclear membrane in multidrug resistance: microinjection of epirubicin into bladder cancer cell lines. BJU Int. 2005; 95(7):1091-1098.
44. Ramachandran C, Sauerteig A, Sridhar KS, Thurer RJ and Krishan A. MDR-1 gene expression, anthracycline retention and cytotoxicity in human lung-tumor cells from refractory patients. Cancer Chemother Pharmacol. 1993; 31(6):431-441.
45. Singal PK and Iliskovic N. Doxorubicin-induced cardiomyopathy. N Engl J Med. 1998; 339(13):900-905.
46. Blagosklonny MV. How cancer could be cured by 2015. Cell Cycle. 2005; 4(2):269-278.
47. Blagosklonny MV and Darzynkiewicz Z. Cyclotherapy: Protection of Normal Cells and Unshielding of Cancer Cells. Cell Cycle. 2002; 1(6):375-382.